{"product_id":"kidney-disease-clinical-trialists-8th","title":"Kidney Disease Clinical Trialists 8th Edition 2024","description":"\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003ch3\u003e\u003cstrong\u003eKidney Disease Clinical Trialists 8th Edition 2024\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cstrong\u003e+ Include: 9 videos, size: 17.5 GB\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eKidney Disease Clinical Trialists 8th Edition 2024\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cbr\u003e\u003cbr\u003eThe Kidney Disease Clinical Trialists (KDCT) 8th Edition 2024 Workshop will be held on March 15-16, 2024, in Washington DC. This high-level think tank event will feature an exceptional expert faculty and a limited number of attendees, including distinguished nephrologists, clinical trialists, principal investigators, and statisticians from academia, R\u0026amp;D pharma and device companies, NIH, EMA, PMDA, FDA, and payers.\u003cbr\u003e\u003cbr\u003eThe workshop aims to foster an international exchange of ideas on trial design, conduct, ethics, interpretation, approvability, and implementation encompassing drugs, devices, biomarkers, and therapeutic strategies for kidney disease\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cbr\u003eThe Kidney Disease Clinical Trialists (KDCT) 8th Edition 2024 Workshop is designed for a select group of professionals involved in kidney disease research and clinical trials. The target audience includes:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eNephrologists\u003c\/li\u003e\n\u003cli\u003eClinical trialists\u003c\/li\u003e\n\u003cli\u003ePrincipal investigators\u003c\/li\u003e\n\u003cli\u003eStatisticians\u003c\/li\u003e\n\u003cli\u003eResearchers from academia\u003c\/li\u003e\n\u003cli\u003eProfessionals from R\u0026amp;D pharma and device companies\u003c\/li\u003e\n\u003cli\u003eRepresentatives from regulatory bodies like NIH, EMA, PMDA, and FDA\u003c\/li\u003e\n\u003cli\u003ePayers\u003c\/li\u003e\n\u003cli\u003ePatient advocates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eThis workshop aims to foster an international exchange of ideas on trial design, conduct, ethics, interpretation, approvability, and implementation of therapeutic strategies for kidney disease.\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eSESSION 1 EGFR SLOPE VS EGFR DELTA AS AN ENDPOINT PROS AND CONS.mp4\u003c\/li\u003e\n\u003cli\u003eSESSION 2 COMBINATION THERAPY IN CKD.mp4\u003c\/li\u003e\n\u003cli\u003eSESSION 3 Focus on IGAN.mp4\u003c\/li\u003e\n\u003cli\u003eSESSION 4 Shifting earlg deveIOpment trials from the EGFR UACR ratio paradigm to a multiplexed biomarker enabled strategy.mp4\u003c\/li\u003e\n\u003cli\u003eSESSION 5 Are simplified consents desirable achievable.mp4\u003c\/li\u003e\n\u003cli\u003eSESSION 6 Dialysis and Vascular Access.mp4\u003c\/li\u003e\n\u003cli\u003eSESSION 7 How to assess the renal benefit of weight loss drugs (i.e.drugs that can affect lean bodg mass).mp4\u003c\/li\u003e\n\u003cli\u003eSESSION 8 Endpoints in AKI trials to guide generation of Core Outcome data Set.mp4\u003c\/li\u003e\n\u003cli\u003eSESSION 9 Developing Core Outcomes Sets in AKI trials.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954443817058,"sku":"MED-AMB03636","price":70.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Kidney-Disease-Clinical-Trialists-8th-Edition-2024.png?v=1779376868","url":"https:\/\/meducourse.com\/products\/kidney-disease-clinical-trialists-8th","provider":"Meducourse","version":"1.0","type":"link"}